Most mental health difficulties have their onset in early adolescence. Increasingly, community based primary care is recognised as a critical pathway to early intervention. Despite encouraging initial evaluations, there is an ongoing need for evidence of the outcomes of primary care youth mental health programmes delivered at scale. This brief report examines reliable improvements in psychological distress and user satisfaction data from a national primary care youth mental health programme in the sustainment phase of implementation.

This report takes a multi-methods approach to routine evaluation data. Young people (aged 12–25; N = 8,721) completed Clinical Outcomes Routine Evaluation (CORE-10 and YP-CORE) pre- and post-treatment. Clinical cut offs and a reliable change index (based on established guidelines) were used to report rates of reliable improvement. The analysis examined differences in outcomes based on age, gender, and clinical need. Satisfaction was measured using the youth service satisfaction survey (N = 4,267). Natural language processing techniques were employed to objectively analyse qualitative user feedback.

Most young people presented in the clinical range, with almost two-thirds reporting moderate to severe distress. Statistically significant reductions in distress were observed with large effect sizes (d = 1.08–1.28). Young people in the clinical range demonstrated significantly higher rates of reliable improvement compared to those who presented in the healthy range. In line with similar evaluations, young adults were more likely to achieve improvement and report higher satisfaction. Sentiment analysis of satisfaction data indicated a strong skew towards positive sentiment, with trust, anticipation and joy being predominant. Qualitative feedback pointed to waiting times as an improvement area.

The absence of a control group limits our ability to evaluate the effectiveness of the service interventions. Nonetheless after a decade of service delivery, these results indicate that large scale national youth mental health programmes can achieve satisfaction and clinical outcomes in line with international standards. Further research is needed on the predictors of reliable change, differences across demographic groups and approaches to improving waiting times in primary care.

The incidence of infections from extended-spectrum β-lactamase (ESBL)–producing Enterobacterales (ESBL-E) is increasing in the United States. We describe the epidemiology of ESBL-E at 5 Emerging Infections Program (EIP) sites.

During October–December 2017, we piloted active laboratory- and population-based (New York, New Mexico, Tennessee) or sentinel (Colorado, Georgia) ESBL-E surveillance. An incident case was the first isolation from normally sterile body sites or urine of Escherichia coli or Klebsiella pneumoniae/oxytoca resistant to ≥1 extended-spectrum cephalosporin and nonresistant to all carbapenems tested at a clinical laboratory from a surveillance area resident in a 30-day period. Demographic and clinical data were obtained from medical records. The Centers for Disease Control and Prevention (CDC) performed reference antimicrobial susceptibility testing and whole-genome sequencing on a convenience sample of case isolates.

We identified 884 incident cases. The estimated annual incidence in sites conducting population-based surveillance was 199.7 per 100,000 population. Overall, 800 isolates (96%) were from urine, and 790 (89%) were E. coli. Also, 393 cases (47%) were community-associated. Among 136 isolates (15%) tested at the CDC, 122 (90%) met the surveillance definition phenotype; 114 (93%) of 122 were shown to be ESBL producers by clavulanate testing. In total, 111 (97%) of confirmed ESBL producers harbored a blaCTX-M gene. Among ESBL-producing E. coli isolates, 52 (54%) were ST131; 44% of these cases were community associated.

The burden of ESBL-E was high across surveillance sites, with nearly half of cases acquired in the community. EIP has implemented ongoing ESBL-E surveillance to inform prevention efforts, particularly in the community and to watch for the emergence of new ESBL-E strains.

To characterize and compare the neuropsychological profiles of patients with primary progressive apraxia of speech (PPAOS) and apraxia of speech with progressive agrammatic aphasia (AOS-PAA).

Thirty-nine patients with PPAOS and 49 patients with AOS-PAA underwent formal neurological, speech, language, and neuropsychological evaluations. Cognitive domains assessed included immediate and delayed episodic memory (Wechsler Memory Scale-Third edition; Logical Memory; Visual Reproduction; Rey Auditory Verbal Learning Test), processing speed (Trail Making Test A), executive functioning (Trail Making Test B; Delis-Kaplan Executive Functioning Scale – Sorting), and visuospatial ability (Rey-Osterrieth Complex Figure copy).

The PPAOS patients were cognitively average or higher in the domains of immediate and delayed episodic memory, processing speed, executive functioning, and visuospatial ability. Patients with AOS-PAA performed more poorly on tests of immediate and delayed episodic memory and executive functioning compared to those with PPAOS. For every 1 unit increase in aphasia severity (e.g. mild to moderate), performance declined by 1/3 to 1/2 a standard deviation depending on cognitive domain. The degree of decline was stronger within the more verbally mediated domains, but was also notable in less verbally mediated domains.

The study provides neuropsychological evidence further supporting the distinction of PPAOS from primary progressive aphasia and should be used to inform future diagnostic criteria. More immediately, it informs prognostication and treatment planning.